Topical cyclosporin A and mitomycin C injection as adjunctive therapy for prevention of primary pterygium recurrence.

BACKGROUND AND

OBJECTIVE

The authors evaluated the results of topical cyclosporin A 1% and injected mitomycin C 0.01% use as adjunctive therapy for prevention of primary pterygium recurrence.

PATIENTS AND

METHODS

Eighty eyes of 76 consecutive patients who had pterygium excision surgery in a prospective, interventional clinical trial received conjunctival autografting combined with an immediate postoperative 0.1-cc injection of 0.01% mitomycin C in caruncula were randomized into two groups: those who received postoperative topical application of cyclosporin A and those who did not.

RESULTS

The recurrence rate in patients who received topical application of postoperative cyclosporin A was 7.5% (3 of 40) compared with 17.5% (7 of 40) for patients who did not receive topical application of postoperative cyclosporin A (P = .31). An unexpected and significant finding in women was that those who received cyclosporin A had no recurrences (0 of 26), whereas those who did not receive cyclosporin A did (6 of 25; 24%) (P = .03).

CONCLUSION

Intracaruncular mitomycin C 0.01% and topical cyclosporin A 1% combined with conjunctival autograft is useful in reducing pterygium recurrence.